Literature DB >> 20055262

Treatment of multiple sclerosis.

Marija Bosnjak-Pasić1, Branka Vidrih, Snjezana Miskov, Vida Demarin.   

Abstract

Multiple sclerosis is an autoimmune inflammatory demyelinating disease of the central nervous system, characterized by multifocal inflammatory destruction of myelin, axonal damage and loss of oligodendrocytes. The disease is carried through two stages: inflammatory and degenerative. The most common form of disease in approximately 85% of the cases is RRMS (relapsing-remitting form). The treatment of MS is devided into: treatment of the acute phase of illness, prevention of new relapses and disease progression, and symptomatic treatment. Most of the changes in treatment of multiple sclerosis and most of the news in recent years concerning new drugs are used in the treatment of progression of the disease and prevention of disease relapses. Some of these drugs are registrated in most Europian countries and USA, and others are in various stages of research.

Entities:  

Mesh:

Year:  2009        PMID: 20055262

Source DB:  PubMed          Journal:  Acta Clin Croat        ISSN: 0353-9466            Impact factor:   0.780


  2 in total

1.  CCR5Δ32 Polymorphism Associated with a Slower Rate Disease Progression in a Cohort of RR-MS Sicilian Patients.

Authors:  Rosalia D'Angelo; Concetta Crisafulli; Carmela Rinaldi; Alessia Ruggeri; Aldo Amato; Antonina Sidoti
Journal:  Mult Scler Int       Date:  2011-06-23

2.  Sinomenine reduces iNOS expression via inhibiting the T-bet IFN-γ pathway in experimental autoimmune encephalomyelitis in rats.

Authors:  Bingjie Gu; Yanying Zeng; Cheng Yin; Huijiuan Wang; Xiaofan Yang; Song Wang; Xiaohui Ji
Journal:  J Biomed Res       Date:  2012-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.